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BACKGROUND & AIMS: SMAD4 frequently is lost from colo-
rectal cancers (CRCs), which is associated with the develop-
ment of metastases and a poor prognosis. SMAD4 loss is
believed to alter transforming growth factor b signaling to
promote tumor progression. However, SMAD4 is also a central
component of the bone morphogenetic protein (BMP) signaling
pathway, implicated in CRC pathogenesis by human genetic
studies. We investigated the effects of alterations in BMP
signaling on the invasive and metastatic abilities of CRC cells
and changes in members in this pathway in human tumor
samples. METHODS: We activated BMP signaling in SMAD4-
positive and SMAD4-negative CRC cells (HCT116, HT-29,
SW480, and LS174T); SMAD4 was stably expressed or
knocked down using lentiviral vectors. We investigated the
effects on markers of epithelial–mesenchymal transition and on
cell migration, invasion, and formation of invadopodia. We
performed kinase activity assays to characterize SMAD4-
independent BMP signaling and used an inhibitor screen to
identify pathways that regulate CRC cell migration. We inves-
tigated the effects of the ROCK inhibitor Y-27632 in immuno-
compromised (CD-1 Nu) mice with orthotopic metastatic
tumors. Immunohistochemistry was used to detect BMPR1a,
BMPR1b, BMPR2, and SMAD4 in human colorectal tumors;
these were related to patient survival times. RESULTS: Acti-
vation of BMP signaling in SMAD4-negative cells altered
protein and messenger RNA levels of markers of epi-
thelial–mesenchymal transition and increased cell migration,
invasion, and formation of invadopodia. Knockdown of the BMP
receptor in SMAD4-negative cells reduced their invasive activ-
ity in vitro. SMAD4-independent BMP signaling activated Rho
signaling via ROCK and LIM domain kinase (LIMK). Pharma-
cologic inhibition of ROCK reduced metastasis of colorectal
xenograft tumors in mice. Loss of SMAD4 from colorectal tu-
mors has been associated with reduced survival time; we foundthat this association is dependent on the expression of BMP
receptors but not transforming growth factor b receptors.
CONCLUSIONS: Loss of SMAD4 from colorectal cancer cells
causes BMP signaling to switch from tumor suppressive to
metastasis promoting. Concurrent loss of SMAD4 and normal
expression of BMP receptors in colorectal tumors was associ-
ated with reduced survival times of patients. Reagents that
interfere with SMAD4-independent BMP signaling, such as
ROCK inhibitors, might be developed as therapeutics for CRC.
Keywords: Colon Cancer; Signal Transduction; Transcription;
Tumor Progression.
olorectal cancer (CRC) remains a frequently fatalCdisease because of the high incidence of metastases
for which current therapy is largely unsuccessful. This
makes the understanding of the process of metastasis crit-
ical to improve the prognosis.
Loss of SMAD4 is seen in 30%–40% of CRCs,1 occurs late
in the adenoma-to-carcinoma sequence,2 and is associated
with liver metastases, a poor prognosis, and a poor response
to chemotherapy.3,4 SMAD4 is the central critical signal
transduction element of the transforming growth factor
(TGF)-b signaling pathway. The consequences of loss of
SMAD4 therefore initially were ascribed to the loss of ca-
nonical TGFb signaling. However, in many cancers, TGFb













ATswitches from being a tumor suppressor to become a tumor
promoter, driving invasion and metastasis.5
The nature of the switch that determines whether TGFb
acts as a tumor suppressor or as a tumor promoter has been
the subject of intense research.6,7Mutant p53has been shown
to be one potential explanation,8 however, another study has
shown that SMAD4 mutations bring about this switch.9
To date, most research into the role of SMAD4 in CRC has
focused exclusively on its role as part of the TGFb pathway.
However, SMAD4 is also the central component of the bone
morphogenetic protein (BMP) signaling pathway that we
and others have shown plays an important role in cancer
development.1,10,11 There is even perhaps stronger evidence
for a critical role for the BMP pathway than for the TGFb
pathway in CRC with germline mutations in BMP receptor
1A (BMPR1A) in juvenile polyposis but not in TGFb re-
ceptors,12 and from genome-wide association studies in CRC
multiple associations exclusively within the BMP pathway
(BMP2, BMP4, BMPR1A, and Gremlin1) but none exclusively
within the TGFb pathway, whereas 2 others are involved in
both (SMAD4 and SMAD7).13,14 BMP signaling classically is
regarded as tumor suppressive in CRC, inducing cell dif-
ferentiation and apoptosis of colonic epithelial cells and
negatively regulating Wnt signaling.10,15 However, although
some studies have shown that activation of BMP signaling
results in growth suppression and induction of differentia-
tion in cancer cell lines,10,16 others have found that BMP
activation leads to prometastatic effects.17
In this study, we set out to investigate the role of
BMP signaling in the processes of epithelial–mesenchymal
transition (EMT), invasion, and metastasis in CRC with
particular focus on the role of loss of SMAD4 and SMAD4-
independent signaling (also known as noncanonical or
non-SMAD BMP signaling).Materials and Methods
Invasion Assay
Cells were labeled with 5 mmol/L CellTracker Green 5-chlor-
omethylfluorescein diacetate (CMFDA) (Invitrogen, Breda, The
Netherlands) after which they were detached using trypsin with 2
mmol/L ethylenediaminetetraacetic acid (EDTA). A total of 105
cells/insert were transferred to 8-mmol/L pore size HTS Fluoro-
Blok Cell Culture Inserts (BD Falcon, Breda, The Netherlands) in
medium containing 1% fetal calf serum. The inserts were coated
with 100 mL of a 1:1 mix of serum-free medium and Matrigel (BD
Biosciences, Breda, The Netherlands). Inserts were placed in 24-
well plates (Corning, Inc, Corning, NY) in which 600 mL of 10%
fetal calf serum–containing media without phenol red were pre-
sent. Fluorescence of the invaded cells at the bottom well of the
Transwell was measured every 2 hours using the BioTek Flx800
(BioTek, Winooski, VT). Data were corrected for background
fluorescence and migration start points were set to zero.
Liver Metastases Model
Liver metastasis were generated by injecting 0.5*106 HT29
cells expressing luciferase dissolved in 50 mL of medium:-
Matrigel (1:1) into the spleens of 6-week-old immunocompro-
mised CD1 nude mice (males). The spleen was not removedafter injection. The mice were treated by intraperitoneal in-
jection with 2.5 mg/kg Y-27632 (R&D Systems, Abingdon,
United Kingdom) dissolved in phosphate-buffered saline (PBS)
(n ¼ 9) or with PBS (n ¼ 9) every other day. Weekly biolu-
minescence scans were performed and after 7 weeks the mice
were killed. The model is described in detail in the
Supplementary Materials and Methods section.
Simultaneous Correlative Scanning Electron
and High Numeric Aperture Fluorescence
Microscopy
This new technique uses a combination of correlative scan-
ning electron microscopy and high numeric aperture fluores-
cence microscopy. For a complete microscope set-up and
explanation of tissue and staining methods we refer to 2 articles
from Zonnevylle et al18 and Liv et al,19 and the Supplementary
Materials and Methods section.
Peptide Array
Samples were analyzed using peptide arrays containing
960 fully annotated, disease-related kinase phosphorylation
sites. Procedures for performing the peptide arrays have been
described in detail elsewhere and can be found in the
Supplementary Materials and Methods section.
Tissue Microarray
Immunohistochemistry for SMAD4, BMPR1A, BMPR1B,
BMPR2, TGFb receptor 1 (TGFbR1), and TGFbR2 was per-
formed in colorectal cancer tissue of 145 patients included on a
tissue microarray. Each individual tumor was represented by 3
separate 0.6-mm cores on the tissue microarray as well as 1
core of normal colon mucosa. Patient information and immu-
nohistochemistry protocols can be found in the Supplementary
Materials and Methods section.Results
SMAD4 Loss Switches BMP Signaling From
Tumor Suppressive to Prometastatic
To investigate the effects of BMP signaling in the context
of SMAD4 loss we used the isogenic CRC cell lines HCT116
and HCT116 SMAD4-/-. HCT116 cells are known to express
low levels of BMPR2 and transfection of BMPR2 results in a
major increase in SMAD4-dependent (canonical) BMP
signaling activity measured using a BMP reporter element
(BRE)–luciferase reporter construct (BRE-Luc) as we have
shown previously.1 Transfection of BMPR2 in HCT116
SMAD4-/- cells does not lead to an increase in BRE-
luciferase activity (Supplementary Figure 1A and B). Acti-
vation of BMP signaling in SMAD4-/- cells using BMPR2
transfection results in a decrease in E-cadherin messenger
RNA (mRNA) expression and an increase in vimentin and
the transcription factors SNAI1, SLUG1, and ZEB1, suggest-
ing induction of EMT (Figure 1A). In contrast, activation of
BMP signaling in the SMAD4-expressing HCT116 cells does
not result in EMT, but increases E-cadherin expression,
suggesting a change toward a more epithelial-like state.
TGFbR2 transfection is used as a control because it is known




ATto induce EMT. To confirm the changes seen at the mRNA
level we checked for protein expression changes in E-cad-
herin and vimentin using immunoblot analysis and fluo-
rescent immunocytochemistry and saw similar effects at theprotein level as seen at the mRNA level (Figure 1B and C).
Inhibition of BMP signaling using the small-molecule
BMPR1A inhibitor LDN-193189 in SMAD4-/- cells results
in a change to more epithelial-like cells (Supplementary
July 2014 Loss of SMAD4 Alters BMP Signaling 199Figure 1C). We also reconstituted SMAD4 expression in
SMAD4-negative CRC cells and observed a change into more
epithelial-like cells based on E-cadherin and vimentin RNA
expression (Supplementary Figure 1D).
To assess changes in the functional aspects of the cancer
cells we used scratch wound healing and Matrigel–
Transwell invasion assays. After BMPR2 transfection an
increase in migration and invasion can be seen in the
HCT116 SMAD4-/- cells, but not in the SMAD4-positive cells
(Figure 1D and E). We also reduced BMP signaling by
silencing individual BMP receptors in the SMAD4-negative
cell line SW480 and measured invasion over 36 hours.
SW480 cells, in contrast to HCT116 cells, express high levels
of BMP receptors, making them more suitable for BMP re-
ceptor silencing experiments.1 Knockdown of BMP receptor
expression results in a decrease in invasion (invasion assay
is shown in Figure 1F, Supplementary Figure 1 shows
Western blots of BMP-receptor knockdown). Knockdown of
BMPR1B leads to the most pronounced decrease in invasion,
followed by knockdown of BMPR2.
Critical experiments were repeated using different BMP
activation methods and different SMAD4-negative cell lines
to avoid cell-line–specific bias (Supplementary Figure 1E–H).
Overall, these data suggest that BMP signaling switches to a












ATSMAD4-Independent BMP Signaling Changes
Cell Shape and Increases Invadopodia
Phase-contrast images of SMAD4-independent BMP
activation showed changes in cell shape with an increase in
small cell protrusions (data not shown). To analyze these
protrusions we used a new technique in which scanning
electron microscopy and wide-field immunofluorescence
can be combined simultaneously.18,19 SMAD4-independent
BMP signaling was activated by transfection of BMPR2 in
HCT116 SMAD4-/- cells, which resulted in more spindle-like
cells (Figure 2A) with polarized distribution of actin and
cortactin. There was also an increase in the number and size
of protrusions. To confirm this observation we used an
established and recognized technique in which co-
localization of actin and cortactin molecularly identifies
the presence of invadopodia.20 We calculated the amount of
cells with invadopodia in the BMPR2-transfected cells and=
Figure 1. SMAD4-independent BMP signaling induces EMT,
signaling in HCT116 SMAD4-/- and HCT116 cells using BMPR2
chain reaction results, corrected for glyceraldehyde-3-phosph
control values are set to 1. (B) Immunoblot analysis of E-cadher
control. (C) Immunofluorescence staining of E-cadherin and v
used to visualize cell nuclei. Scale bars: 50 mm. (D) Wound heali
and HCT116 SMAD4-/- cells were transfected transiently with
confluent cells. (E) Invasion of HCT116 and HCT116 SMAD4-
Transwell system. Cells were transfected transiently with pcDN
and seeded in the upper chamber of a Transwell system. (F) Inv
RNA against BMPR1A, BMPR1B, BMPR2, or scrambled small in
control. Nontransfected SW480 cells were used as an additiona
means of the individual experiments (*<.05, **<.001, ***<.001).compared this with the control. A higher percentage of cells
with invadopodia were seen in the condition in which
SMAD4-independent BMP signaling was activated
(Figure 2B and C). A separate analysis of cell shape changes
showed that BMP activation in the SMAD4-/- cells resulted
in more spindle-shaped cell morphology typical of mesen-
chymal cells (Supplementary Figure 2).
Comprehensive Analysis of the SMAD4-
Independent BMP Signaling Cascade Using
Kinome Profiling
To assess the kinase activity changes associated with
SMAD4-independent BMP signaling, HCT116 SMAD4-/- cells
were transfected with BMPR2 or the empty pcDNA
vector and subsequently a PepChip (Pepscan, Lelystad,
The Netherlands) array was performed21,22 (Supplementary
Figure 3). The most prominent effects seen in the peptide
arrays were activation of signaling pathways responsible for
cell migration, cell survival, and proliferation (Figure 3A). To
establish the validity of the kinome profiling data the most
consistent kinase activity changes were confirmed by
immunoblotting with activation-specific antibodies against
pAKT, p-glycogen synthase kinase a/b, pp38MAPK, pMKK3/
6, pJNK, pERK, p-LIMK, and SIP1 (Figure 3B).
We also activated noncanonical SMAD4-independent
TGFb signaling by transfecting TGFbR2 into HCT116
SMAD4-/- cells. Our result show that SMAD4-independent
BMP signaling is similar to SMAD4-independent TGFb
signaling, although the activation and phosphorylation of
AKT is more prominent in cells transfected with TGFbR2
than with BMPR2. Both signaling pathways are comparable
in activating the Wnt pathway, but SMAD4-independent
BMP signaling has more effect on the expression of SIP1/
ZEB2, a member of the dEF-1 family of 2-handed zinc finger
nuclear factors associated with EMT.
SMAD4-Independent BMP Signaling Induces
EMT and Invasion via the ROCK Pathway
Having established that SMAD4-independent BMP
signaling induces EMT, migration, and invasion, and having
identified the downstream signaling pathways involved, we
set out to screen for which of these pathways primarily
is responsible for the induction of EMT. We inducedmigration, and invasion. (A) Activation of BMP and TGFb
and TGFbR2 transient transfection. Quantitative polymerase
ate dehydrogenase expression, are presented and pcDNA
in and vimentin protein expression. Actin is used as a loading
imentin protein expression. 40,6-diamidino-2-phenylindole is
ng assay showing the wound healing after 24 hours. HCT116
pcDNA, BMPR2, or TGFbR2 and a scratch was made in
/- cells measured over a 36-hour time period in a Matrigel–
A or BMPR2, labeled with the fluorescence label Cell tracker,
asion of SW480 cells transfected with either small interfering
terfering RNA. Scrambled small interfering RNA was used as a
l control. Student t tests were performed using the corrected
Data are presented as means  SEM.
Figure 2. SMAD4-independent BMP signaling increases invadopodia formation. (A) HCT116 SMAD4-/- cells were grown on
ITO slides coated with poly-L-lysin and gelatin. Cells were transfected transiently with either pcDNA or BMPR2. After 24 hours
the cells were fixed and stained for cortactin (mouse-anticortactin and anti-mouse AlexaFluor 594 nm) and actin (phalloidin,
488 nm). The indium-tin-oxide slides were placed in a simultaneous correlative scanning electron and high numeric aperture
fluorescence microscope. Figures 1–7 are pcDNA samples. Figures 8–14 are BMPR2 samples. Figures 1–4 and 11–14 show
that BMPR2-transfected cells show more cell protrusions. Figures 5–10 show the change in cell shape and actin/cortactin
distribution after BMPR2 transfection. (B) Phalloidin 488 was used to stain for actin and mouse-anticortactin plus anti-mouse
AlexaFluor 594 for visualization for cortactin. Before staining, HCT116 and HCT116 SMAD4-/-cells were transfected transiently
with either pcDNA or BMPR2. Scale bar: 5 mmol/L. This figure only shows the HCT116 SMAD4-/- cells. Quantification of the
experiment presented in panel B. Cells with co-localization of cortactin and actin were counted as having invadopodia. A cell
showing 1 or more invadopodium was counted as positive. One hundred cells per condition were analyzed. The Student t test
was performed using the means of the individual experiments (*<.05, **<.01, ***<.001). Data are presented as means  SEM.


















ATSMAD4-independent BMP signaling using BMPR2 trans-
fection in SMAD4-negative cells, treated the cells with a
series of kinase inhibitors, and assessed vimentin expres-
sion by quantitative polymerase chain reaction (q-PCR). The
use of pharmacologic inhibitors has the advantage that in-
hibitors can be tested further relatively easily as potential
new CRC treatment options. Based on the reduction of
vimentin expression (Figure 3C), the ROCK inhibitor
Y-27632 is the most potent inhibitor of BMP-induced EMT.
SMAD4-Independent BMP Signaling Activates
the Rho/ROCK/LIMK Pathway
Our next step was to investigate the connection between
the BMP pathway and the ROCK pathway and to further
evaluate the effects of ROCK inhibition.
First, we further assessed the role of SMAD4 in BMP-
induced ROCK pathway activation. Activation of the BMP
pathway in HCT116 SMAD4-/- cells lead to an increase in the
phosphorylation of the Rho/ROCK downstream targets
LIMK1/2 and cofilin (Figure 4A), but not in SMAD4-positive
cells. Treatment with the ROCK inhibitor Y-27632
(2.5 mmol/L) lead to a decrease of phosphorylated ROCK
downstream targets and an abolition of the effect of BMP
pathway activation on the ROCK pathway in SMAD4-/- cells.
Previous in vitro studies using Y-27632 have used various
concentrations depending on the cell type (1–20 mmol/L).23
In our experimental set-up, 2.5 mmol/L was the lowest con-
centration in which a major p-cofilin down-regulation could
be seen (Supplementary Figure 4A). A direct connection
between the BMP and ROCK pathways was investigated by
transfecting cells with an HA-tagged BMPR2 construct,
immunoprecipitating BMPR2 using anti-HA antibodies, and
immunoblotting for LIMK (Figure 4B). This suggests a direct
association between LIMK and BMPR2 in these cells.
Y-27632 abolishes the increase in wound healing, inva-
sion, and invadopodia seen after the activation of SMAD4-
independent BMP signaling, showing that the effects of the
BMP pathway on cell shape and migration/invasion are
ROCK dependent (Figure 4C–E). We saw the same effects
using different cell lines and both ligand and receptor-based
BMP activation (Supplementary Figure 4B–E).
The ROCK Inhibitor Y-27632 Reduces
Metastases in an Orthotopic Liver Metastasis
Model of SMAD4-Negative Colorectal Cancer
To test the antimetastatic effects of ROCK inhibition we
used a mouse model of liver metastasis in which firefly-
luciferase–expressing human CRC cells are injected into the
spleens of immunocompromised CD-1 Nu mice. The devel-
opment of liver metastases was evaluated weekly using
bioluminescence scans and after 7 weeks the mice were kil-
led. We used the SMAD4-negative CRC cell line HT-29, which
resulted more consistently in liver metastases in our hands
than HCT116 and SW480. Activation of BMP signaling in HT-
29 also leads to the same increase in invasion without
changes in cell viability in vitro comparable with other
SMAD4-negative cell lines (Supplementary Figure 5A–C).
Mice received either 2.5 mg/kg of Y-27632 dissolved in PBSor PBS intraperitoneally every other day. Eight of 9 of the
control mice compared with 3 of 9 of the Y-27632–treated
mice developed liver metastases (Figure 5A). There was a
significant difference in total luminescence at week 7
between the control mice and the Y-27632–treated mice
(Figure 5B). Quantification of the total whole-mouse scans is
correlated closely with the quantification of ex vivo liver
scans (R2 ¼ 0.95), showing that liver metastasis formation
can be followed using in vivo whole-mouse scans in
this model (Supplementary Figure 5D). Multiple random
sections per liver were analyzed microscopically using H&E.
Metastases could be found in 8 of 9 of the control mice
compared with 3 of 9 of the Y-27632–treated mice
(Supplementary Figure 5G). Mice treated with Y-27632 had a
significantly lower liver weight and volume (Supplementary
Figure 5E and F).SMAD4-Independent BMP Signaling Leads
to a Poorer Prognosis
Several studies consistently have shown that loss of
SMAD4 expression in CRC is associated with a worse
prognosis in patients.24,25 Our in vitro data suggest that
this could be the result of SMAD4-independent BMP
signaling. In a previous analysis of the expression of ele-
ments of the BMP pathway in CRC we observed frequent
aberrant expression of the BMP receptors.1 We therefore
would expect that concurrent loss of BMP-receptor
expression would lead to a better prognosis in patients
with SMAD4-negative cancers by reducing this SMAD4-
independent BMP signaling. In other words, the poor
prognosis associated with loss of SMAD4 would be ex-
pected to be dependent on the presence of normal BMP-
receptor expression in the tumor.
We mapped the expression patterns of SMAD4 and BMP
receptors in patients using immunohistochemistry for
SMAD4, BMPR1A, BMPR1B, and BMPR2 in a tissue micro-
array in 145 CRCs. Immunostaining was scored according to
the system described in the Supplementary Materials and
Methods section and cancers subsequently were ascribed
to 1 of 4 categories based on the expression of SMAD4 and
BMP receptors. Cancers were divided into SMAD4 positive
and SMAD4 negative and these 2 groups then were sub-
divided into BMP-receptor positive and BMP-receptor
negative. A patient was considered BMP-receptor negative
if any 1 of the 3 BMP receptors had aberrant expression.
A total of 40.7% of the tumors had negative SMAD4
immunostaining, which is consistent with other studies
(Supplementary Figure 6A and B). Subdivision of the
SMAD4-negative cancers into BMP-receptor positive and
BMP-receptor deficient showed that the presence of normal
BMP-receptor expression in the SMAD4-negative tumors is
associated with a poor prognosis (P ¼ .005) (Figure 6A),
suggesting that SMAD4-independent BMP signaling leads to
a worse prognosis in patients. Conversely, patients with
SMAD4-negative tumors with impaired BMP-receptor
expression have a survival similar to those with normal
SMAD4 expression. The poor prognosis found in cancers
with SMAD4-independent BMP signaling is not independent





July 2014 Loss of SMAD4 Alters BMP Signaling 203of tumor stage. This is probably because BMP-receptor
expression in SMAD4-negative cancers is associated
weakly with stage (Supplementary Figure 6C). Interestingly,
there is no correlation between the poor prognosis seen in
SMAD4-negative cancers and TGFb-receptor expression
(P ¼ .75) (Figure 6C, Supplementary Figure 6C and E show
TGFb-receptor expression frequencies and stage distribu-
tion). These findings are consistent with the conclusion that
the poor prognosis seen in patients with SMAD4-negative
cancers is owing to active SMAD4-independent BMP













The data we present show that the BMP signaling
pathway, which is awell-known tumor-suppressive pathway,
changes into a prometastatic pathway upon loss of SMAD4.
The current paradigm is that the poor survival associated
with loss of SMAD4 is the result of effects on TGFb signaling.
We show that BMP signaling in the absence of SMAD4 leads to
the activation of a broad range of signaling pathways and
enhances invasion and metastasis.
BMP signaling has been associated previously with
invasiveness. For example, BMP2 increases the motility and
invasiveness of gastric cancer cell lines26 and BMP4 in-
duces EMT in ovarian cancer cell lines,27 but the accepted
view of BMP signaling is that of a tumor suppressor28 and a
barrier to tumor progression and metastasis (reviewed by
Wakefield and Hill29). Here, we show that BMP signaling
can be tumor promoting by increasing EMT and invasive-
ness in CRC and we show that this depends on the
expression of SMAD4. A similar dual role has been seen
with TGFb, which initially is tumor suppressive but
switches to tumor promoting in the later stages of cancer
progression.30
The activation of SMAD4-independent BMP signaling
also results in an increase in invadopodia. Invadopodia are
transformed podosomes with the ability to degrade the
extracellular matrix,31 allowing a transition to a more
mesenchymal-like state.32 Identification of invadopodia can
be performed by co-localization of cortactin and actin,20
which we used in our assay. We performed imaging in the
same cells using a newly developed combined simultaneous
correlative scanning electron microscope and a high
numeric aperture fluorescence microscope that allowed us=
Figure 3. Peptide array analysis of SMAD4-independent BMP
siently with either pcDNA or BMPR2. A PepChip peptide array
and Methods section. In the peptide array, phosphorylation ch
results were categorized according to well-known signaling path
within the pathway, as well as the changes in the whole pathwa
see Supplementary Figure 4. (B) Validation of the results of kinom
were transfected transiently with either pcDNA or BMPR2. Sub
from a commercial inhibitor screening kit. The median inhibito
Methods section) was used for each inhibitor. RNA was isolate
for vimentin expression. Glyceraldehyde-3-phosphate dehydro
presented as relative to the vimentin expression in the control co
means of the individual experiments (*<.05, **<.001, ***<.001).to visualize the distribution of actin and cortactin using
fluorescent microscopy and the cell shape protrusions using
scanning electron microscopy simultaneously.19 The fluo-
rescent image does not show the typical spots of
co-localized actin and cortactin seen at the tip of invado-
podia with confocal microscopy because of the use of a
wide-field fluorescent microscope that does not eliminate
the light outside the focal plane. The combined fluorescent
and electron microscope images do show an increase in cell
protrusions and a change in the actin/cortactin distribution,
implying a change in cell polarity associated with EMT33
after activation of SMAD4-independent BMP signaling.
Kinome profiling analysis showed that SMAD4-
independent BMP signaling activates a complex network
of kinases. Among others, p38MAPK, ERK, JNK, PI3K, AKT,
glycogen synthase kinase (GSK), and LIMK are activated
targets of pathways involved in inflammation, mitosis,
cell survival, proliferation, stemness, and cytoskeleton
rearrangement.
The activation of p38MAPK, ERK, and JNK is consistent
with previous reports of SMAD4-independent BMP7
signaling.34 Other changes have not been described before
and include inhibition of GSKa/b, which is part of the Axin/
adenomatous polyposis coli (APC)/GSK complex respon-
sible for degrading b-catenin. Inhibiting GSK leads to an
increase in b-catenin and thereby an increase in Wnt
signaling activity. BMP signaling is known to oppose Wnt
signaling,15 but not to enhance it as we observe here in
SMAD4-negative cells. Although we show activation of AKT
owing to activation of BMP signaling in SMAD4-negative
cells, BMP signaling has been shown to inhibit prolifera-
tion via dephosphorylation of AKT in adrenocortical
carcinomas.35
The Rho/ROCK/LIMK pathway is involved in the reor-
ganization of the cytoskeleton and in cell migration. BMP7 is
known to activate the Rho/ROCK pathway in fibroblasts.36 It
also is known to act downstream of BMP in neural devel-
opment37 and osteogenesis,38 but is not known to be a part
of the BMP signaling cascade in epithelial cells. BMPR2
is known to interact directly with LIMK,39 which we
confirmed in our experimental set-up. This may explain the
connection between SMAD4-independent BMP signaling
and the Rho/ROCK/LIMK pathway in CRC. We show that the
Rho/ROCK/LIMK pathway is a critical component of the
SMAD4-independent BMP signaling driving invasion andsignaling. (A) HCT116 SMAD4-/- cells were transfected tran-
was performed as described in the Supplementary Materials
anges in the substrates of 960 kinases were measured. The
ways. A selection of the individual changes of specific targets
y, is presented. For a full list of the kinome profiling changes
e profiling using immunoblotting. (C) HCT116 SMAD4-/- cells
sequently, cells were treated with different kinase inhibitors
ry concentration (found in the Supplementary Materials and
d and quantitative polymerase chain reaction was performed
genase was used as a control. The vimentin expression is
ndition. The Student t test was performed using the corrected
Data are presented as means  SEM.




ATmetastasis and represents a sensitive pharmacologic target
by which to inhibit this. Clinically, ROCK is an interesting
target for treatment because ROCK inhibitors, known by the
name Fasudil, already have been used in patients. The use of
Fasudil in patients with pulmonary hypertension and cere-
bral vasospasm did not lead to severe side effects.40,41
However, further safety assessment is imperative consid-
ering the fact that ROCK inhibition in mouse embryos
resulted in developmental defects.42Loss of SMAD4 protein expression is one of the best
molecular prognostic markers in CRC.24 This is thought to be
owing to loss of antimetastatic SMAD4-dependent TGFb
signaling.9 However, when we subdivide patients with
SMAD4-negative CRC into 2 groups according to the
expression of BMP receptors, only the SMAD4-negative tu-
mors that express high levels of BMP receptors have a poorer
prognosis. Those with low BMP receptor expression have a
prognosis similar to patients with SMAD4-positive CRC. In a
Figure 5. The ROCK inhibitor Y-27632 reduces colorectal cancer metastases in an orthotopic mouse model of liver metas-
tasis. HT-29 cells (105), which naturally express no SMAD4, stably transfected with an optimized firefly luciferase construct,
were injected into spleens of CD-1 Nu mice suspended in 50 mL of medium:Matrigel (50:50). Mice were treated with an
intraperitoneal injection of either PBS (n ¼ 9) or Rock inhibitor (2.5 mg/kg) (n ¼ 9) every other day. Weekly bioluminescence
scans were used to visualize liver metastasis formation. Seven weeks after the intrasplenic injection the mice were killed.
(A) Bioluminescence whole-mouse scans at week 7. (B) Quantification of the whole-mouse scans at week 7. Comparison was
made using the Student t test.













ATsimilar analysis, TGFb-receptor expression shows no corre-
lation with prognosis. BMPR and TGFb-receptor expression
in SMAD4-negative CRC are both associated with more
advanced stage, therefore, the association with prognosis is
not independent of stage. Nevertheless, we believe this pro-
vides preliminary evidence in human beings that the BMP
and not the TGFb pathway is responsible for the poor
prognosis associated with loss of SMAD4. It also suggests that
SMAD4 is a good prognostic marker owing to its central role
in the BMP pathway and not simply because it is a surrogate
marker for aneuploidy as has been suggested.43 Furthermore,
SMAD4 potentially can be refined as a prognostic marker by
analysis of BMP-receptor expression.=
Figure 4. SMAD4-independent BMP signaling activates the Rh
and HCT116 SMAD4-/- cells. Cells were transfected transiently
treated with 2.5 mmol/L of ROCK inhibitor or PBS. Blots were in
was used as a loading control. (B) HCT116 SMAD4-/- cells were
and HA tag). Cells were lysed and immunoprecipitation was perf
Subsequently, Western blot analysis was performed and blots w
HCT116 and HCT116 SMAD4-/- cells transiently transfected wi
ROCK inhibitor or PBS. After 24 hours, wound healing was qu
either pcDNA or BMPR2. Cells were labeled with Celltracker, see
was measured every 2 hours for 24 hours. (E) Immunofluorescen
of actin and cortactin. Actin was visualized using phalloidin-48
used to visualize cortactin. HCT116 SMAD4-/- cells were transfe
cells were treated with either 2.5 mmol/L of Rock inhibitor or PBS
counted. If a cell contained co-localization of cortactin and act
was performed using the corrected means of the individual e
means  SEM.To conclude, we have shown that upon SMAD4 loss, BMP
signaling becomes prometastatic through activation of a
broad program of SMAD4-independent BMP signaling. This
consists of the activation of various downstream signaling
pathways including the Rho/ROCK/LIMK pathway. Our pa-
tient data suggest that BMP signaling and not TGFb signaling
is responsible for the poor prognosis associated with SMAD4
loss and that concurrent analysis of BMPR expression
potentially can improve SMAD4 as a prognostic marker.
These results would suggest that ROCK inhibitors might be a
novel therapeutic approach in the subgroup of colorectal
cancers that have lost SMAD4, a subgroup with a poor
prognosis that respond poorly to current therapy.o/ROCK/LIMK pathway. (A) Immunoblot analysis of HCT116
with either BMPR2 or pcDNA vector. Subsequently, cells were
cubated with antibodies against pLIMK1/2 and p-cofilin. Actin
transfected with BMPR2-HA (plasmid encoding both BMPR2
ormed using HA-tag antibodies and protein A agarose beads.
ere exposed to LIMK antibodies. (C) Wound healing assay of
th either pcDNA or BMPR2 and treated with either 2.5 mmol/L
antified. (D) Invasion of HCT116 SMAD4-/- transfected with
ded in the upper chamber of a Transwell system, and invasion
ce pictures visualizing invadopodia by showing co-localization
8. Mouse-anticortactin plus anti-mouse AlexaFluor 594 was
cted transiently with either pcDNA or BMPR2. Subsequently,
for 24 hours. For quantification, 100 cells per condition were
in it was counted as invadopodia positive. The Student t test
xperiments (*<.05, **<.01, ***<.001). Data are presented as
Figure 6. The influence of
BMP-receptor expression
in SMAD4-negative can-
cers. (A) CRC tissue from
145 patients was stained
for SMAD4, BMPR1A,
BMPR1B, and BMPR2 us-
ing immunohistochemistry
in a tissue microarray.
Three cores per cancer
were evaluated. For scoring
methods and patient in-
formation see the
Supplementary Materials
and Methods section. The
graph shows a Kaplan–
Meier survival curve based
on SMAD4 and BMP-
receptor expression.
SMAD4 loss leads to
poorer survival. Closer in-
vestigation of the SMAD4-
negative group showed
that a subgroup of patients
with cancers that ex-
pressed BMP receptors
had a poorer prognosis
than patients who had
reduced BMP-receptor
expression. (C) Similar
analysis as in panel B, but
based on the expression
levels of TGFb receptors
(1 and 2) instead of BMP
receptors.
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Supplementary Materials and Methods
Cell Culture
SW480, HT29, DLD1, and HCT116 colon cancer cell lines
were obtained from the American Type Culture Collection
(Manassas, VA) and cultured in Dulbecco’s modified Eagle
medium (Gibco, Paisley, Scotland) with 4.5 g/L glucose and
580 mg/L L-glutamine. This was supplemented with peni-
cillin (50 U/mL) and streptomycin (50mg/mL) andwith 10%
fetal calf serum (Gibco) unless stated otherwise. HCT116
SMAD4-/- cells were kindly provided by Dr Bert Vogelstein
(Johns Hopkins University, Baltimore, MD). HCT116
SMAD4-/- cells were cultured in Dulbecco’s modified
Eagle medium supplemented with 0.4 mg/mL G418 and
0.1 mg/mL hygromycin B. All in vitro experiments were
performed on cells growing exponentially.
Activation or Inhibition of BMP Signaling
Activation. Treatment with BMP-2 ligand (100 ng/mL)
(BD Biosciences) dissolved in Dulbecco’s modified Eagle
medium supplemented with 1% fetal calf serum was
compared with the same volume of PBS dissolved in Dul-
becco’s modified Eagle medium supplemented with 1%
fetal calf serum, or transfection of a pcDNA4/TO plasmid
(Invitrogen) expressing BMPR2 was compared with trans-
fection of an empty vector pcDNA4/TO.
Inhibition. Recombinant human noggin (500 ng/mL)
(BD Biosciences) or the small molecule LDN-193189
(5 nmol/L) (Selleckchem, Houston, TX) in culture medium.
The controls were PBS and dimethyl sulfoxide, respectively,
added in the same volume to the culture medium.
Transfection, Luciferase Reporter Assay, and
Small Interfering RNA Knockdown
Cells were transfected transiently with either a pcDNA4/
TO*BMPR2-expressing plasmid, a pcDNA4/TO*TGFbR2-
expressing plasmid, or a pcDNA4/TO control vector (Invi-
trogen). The efficiency of the transfection was evaluated by
co-transfection with a pmaxGFP control vector (Amaxa
GmbH, Cologne, Germany) and the measurement of GFP-
positive cells, which was at least 70%. The activity of
canonical BMP and TGFb signaling was measured using
co-transfection of BRE-Luc vector or CAGA-Luc vector,
respectively, and a cytomegalovirus promoter-driven Renilla
luciferase vector (Promega, Leiden, The Netherlands).
Transfections were performed using Lipofectamine 2000
(Invitrogen). Twenty-four hours after transfection the lucif-
erase activity was assayed using a Dual-Glo Luciferase Assay
System (Promega) on a Luminometer (Berthold Technolo-
gies, Bad Wildbad, Germany). Each firefly luciferase value
was corrected for its co-transfected renilla luciferase value.
For small interfering RNA knockdown of BMP receptors,
cells were transfected with either small interfering RNA
against one of the BMP receptors (BMPR1A, BMPR1B, or
BMPR2), or scrambled small interfering RNA (all Ambion,
Invitrogen) using Lipofectamine 2000 (Invitrogen)
(BMPR1A Ambion Silencer Select Pre-designed siRNA ID:
s280, BMPR1B Ambion Silencer Select Pre-designed siRNA
ID: s2041, and BMPR2 Ambion Silencer Select Pre-designed
siRNA ID: s2045).
Stable Short Hairpin RNA-Mediated Knockdown
of SMAD4
Lentiviral constructs expressing short hairpin RNAs
targeting SMAD4 (TRCN0000040028) and a nontargeting
control construct (SHC002) were obtained from the Sigma
mission short hairpin RNA library (Sigma-Aldrich, St. Louis,
MO). Production of lentiviruses by transfection into 293T
cells has been described earlier.1 Cells were transduced in
the presence of 8 mg/mL polybrene (Sigma-Aldrich). Cells
were selected using puromycin.
Wound Healing Assay
Cells were plated in 6-well plates (Corning, Inc) and
grown in a monolayer until 70%–80% confluent. At this
point, a scratch was made using the tip of a micropipette.
Bright-field images were obtained at 0 hours and after 24
hours and cell migration was calculated using ImageJ soft-
ware version 1.46 (National Institutes of Health, Bethesda,
MD; available: rsbweb.nih.gov/ij/) as the ratio of the wound
closure relative to the initial wound.
Roundness
Phase-contrast images of HCT116 and HCT116 SMAD4-/-
cells were obtained using a Zeiss Axiovert 200m (Sliedrecht,
The Netherlands). Images were analyzed using ImageJ soft-
ware and the roundness was calculated using the following
principle. Roundness (R) is based on a circularity ratio be-
tween the surface area of the cell and a perfect circle that has
the same perimeter as the cell. The roundness can be calcu-
lated using 2 variables, namely surface area (A) and the
perimeter (P). The given formulas for a perfect circle with
R¼1 are as follows: A¼pr2, and P¼pr or r¼P/2p, and then
substituting the radius in A provides the following: A ¼ p
(P/2p)2/ A ¼ pP2/(4p2)/ A ¼ P2/4p. If the R is a ratio
between the surface area of the test shape and the surface
area of a perfect circle then R¼Acell/Acircle.With the previous
area of a perfect circle filled into the equation it provides the
following: R ¼ Acell/(P2/4p) or R ¼ 4p (A/P2).
In this formula, a perfect circle is equal to 1 and a line
approaches 0. The roundness of 100 cells per condition was
measured in each experiment.
Kinase Inhibitor Screen
Cells were grown in 6-well plates. Cells were transfected
with either pcDNA or BMPR2 when 60% confluent, after
which the cells were treated with kinase inhibitors
(Supplementary Table 1 shows the concentrations). After
24 hours of treatment the cells were lysed using TRIzol and
RNA was isolated. A reverse-transcription polymerase chain
reaction was performed for the expression of vimentin (see
following paragraph for protocol).
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Real-Time Polymerase Chain Reaction
Total RNA was isolated using TRIzol (Invitrogen) ac-
cording to the manufacturer’s instructions. Complementary
DNA was synthesized from 1 mg of total RNA using random
primers (Promega) and MMLV-reverse transcriptase (Invi-
trogen). Polymerase chain reaction was performed using
the iCycler Thermal Cycler and the iQ5 Multicolor
Real-Time Polymerase Chain Reaction Detection System
(Bio-Rad, Santa Cruz, CA). Glyceraldehyde-3-phosphate de-
hydrogenase expression was used to normalize for variance.
Details of the primers used are shown in Supplementary
Table 2.
Immunoblotting
Cells were grown in 6-well plates. Cells were washed
with PBS and cell lysis buffer (Cell Signaling Technology,
Beverly, MA) plus protease inhibitor (Pierce Biotechnology,
Rockford, IL) was added. The cells were lysed on ice for 15
minutes, scraped into 1.5-mL tubes (Eppendorf, Hamburg,
Germany), sonicated, and centrifuged for 10 minutes at
14,000 rpm at 4C. Protein levels were measured with a
BCA kit (Pierce Biotechnology) using clear lysates. The
protein levels in each sample were equalized, the lysates
were mixed with 3 sodium dodecyl sulfate sample buffer
(125 mmol/L Tris/HCl, pH 6.8; 4% sodium dodecyl sulfate;
3% b-mercaptoethanol; 20% glycerol, bromphenol blue),
and were boiled at 97C for 5 minutes. The proteins were
separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and blotted onto a polyvinylidene difluoride
membrane (Millipore, Billerica, MA). The blots were blocked
in blocking buffer containing 5% nonfat dry milk (Bio-Rad)
dissolved in Tris-buffered saline supplemented with 0.05%
Tween-20 and washed 3 times in the Tris-buffered saline
supplemented with 0.05% Tween-20. Both primary and
secondary antibodies were dissolved in 0.5% nonfat dry
milk. The primary antibody was incubated overnight at 4C
(see Supplementary Table 3 for antibodies used and di-
lutions) in 0.1% nonfat dry milk– Tris-buffered saline
supplemented with 0.05% Tween-20. Secondary horse-
radish-peroxidase–linked antibody was incubated for 1
hour at room temperature with 0.1% nonfat dry milk–Tris-
buffered saline supplemented with 0.05% Tween-20. Blots
then were exposed to Lumilightþ (Roche, Basel,
Switzerland) chemiluminescent substrate and visualized
using a chemiluminescence imager (Bio-Rad).
Immunoprecipitation
HA tag antibodies (Cell Signaling) were added to the cell
lysate (1:150) and incubated with gentle rocking overnight
at 4C. Afterward, protein A agarose beads (Cell Signaling)
(20 mL) were added and lysate was incubated with gentle
rocking for 3 hours at 4C. Lysate was spun down and the
pellet was washed 5 times with 500 mL of cell lysis buffer.
The pellet was resuspended in 20 mL 3 sodium dodecyl
sulfate sample buffer and heated to 97C for 5 minutes.
Subsequently, the samples were loaded on a sodium
dodecyl sulfate–polyacrylamide gel.
Immunofluorescence
Alexa Fluor 488 phalloidin was obtained from Invi-
trogen. Anticortactin (p80/85) (mouse), clone 4F11 was
obtained from Millipore. Anti-mouse AlexaFluor 594 was
obtained from Invitrogen. For immunofluorescence, cells
were adhered to poly-l-lysine–coated (Sigma-Aldrich) cov-
erslips, fixed in 4% paraformaldehyde, stained in per-
meabilization buffer (PBS containing 0.05% Triton X-100
[Sigma-Aldrich, Zwijndrecht, The Netherlands]), and
embedded in SlowFade Gold (Invitrogen). Images were
obtained on a Leica TCS SP2 laser scanning spectral
confocal microscope equipped with 488-nm argon and 543
HeNe lasers (Leica, Mannheim, Germany) and processed
using ImageJ software.
Simultaneous Correlative Scanning Electron and
High Numeric Aperture Fluorescence
Microscopy
The following section contains a summary of the mi-
croscopy set-up. For a complete microscope set-up and
explanation of tissue and staining methods we refer to 2
reports by Liv et al2 and Zonnevylle et al.3
All imaging experiments were performed on a fluores-
cence microscope integrated into a commercial Scanning
Electron Microscope (Quanta 200 FEG microscope; FEI,
Eindhoven, The Netherlands) as developed at Delft Uni-
versity of Technology and DELMIC BV (Delft, The
Netherlands). The fluorescence microscope was equipped
with a 100 1.4 numeric aperture objective lens (Nikon CFI
Plan Apochromat VC) mounted below the sample holder in
the Scanning Electron Microscope chamber, and excitation
and emission filters for AlexaFluor 488.
Seeding and Transfection
ITO-coated microscope slides (thickness #1, 22 22 mm
with 8–12 Usq-1 or 22  40 mm with 70–100 Usq-1; SPI
Supplies, West Chester, PA) were disinfected with 70%
ethanol, placed in culture dishes with the conductive side
upward, and incubated with culture medium. The cells were
seeded onto the ITO-coated glass slides.When cells reached a
confluence of 60% they were transfected with either
pcDNA4/TO or BMPR2 and cultured for 48 hours at 37C in
5% CO2. Cells then were washed twice with PBS and fixed for
10 minutes with a mixture of 2.5% paraformaldehyde and
1.25% glutaraldehyde in 0.1 mol/L PBS, pH 7.4. Samples
were washed 3 times with PBS after fixation.
Fluorescent Labeling and Immunocytochemistry
Actin was stained using AlexaFluor 488 phalloidin
(Invitrogen) in a 1:40 PBS/1% bovine serum albumin/0.1%
Triton dilution for 30 minutes according to the manufac-
turer’s instructions. Afterward, samples were washed 3
times with PBS.
For the immunocytochemistry of cortactin, cells were
incubated with the primary antibody in PBS/1% bovine
serum albumin/0.1% Triton (1:200) for 30 minutes at room
temperature and afterward were washed 3 times with PBS.
208.e2 Voorneveld et al Gastroenterology Vol. 147, No. 1
The cells then were incubated with the secondary antibody
(1:200) diluted in PBS/1% bovine serum albumin/0.1%
Triton for 20 minutes at room temperature and then
washed again 3 times with PBS. The primary antibody used
was anticortactin (p80/85) (mouse), clone 4F11 (Millipore),
and the secondary antibody was AlexaFluor 594 goat anti-
mouse IgG (HþL) (Invitrogen). To remove any remaining
salt residue the cells were washed 3 times with dH2O and
left in dH2O at 4C overnight.
Kinase Activity Analysis Using Pepchip
Peptide Arrays
Kinome profiling using peptide arrays exploits the sub-
strate specificity of individual kinases to infer their activity
from changes in the phosphorylation of an array of immo-
bilized peptide kinase substrates. In our approach, we used
peptide arrays containing 960 peptides, each representing a
fully annotated, disease-related kinase phosphorylation site,
which were spotted on Hydrogel-coated glass in triplicate
(the spotting procedure is described by Diks et al4). The
sequence of the peptides involved as well as the source
proteins from which these peptides were derived can be
found in more detail at http://www.pepscan.com/presto/
files/pepchip/PepChip-Kinomics-Map.zip. Procedures for
performing kinome arrays have been described in detail
elsewhere.5,6 Briefly, cells were lysed in 50 mL lysis buffer
(20 mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl, 1 mmol/L
EDTA, 1 mmol/L ethylene glycol-bis(b-aminoethyl ether)-
N,N,N0,N0-tetraacetic acid, 1% Triton X-100, 2.5 mmol/L
sodium pyrophosphate, 1 mmol/L MgCl2, 1 mmol/L glyc-
erophosphate, 1 mmol/L Na3VO4, 1 mmol/L NaF, 1 mg/mL
leupeptin, 1 mg/mL aprotinin, and 1 mmol/L phenyl-
methylsulfonyl fluoride) and 10 mL of the peptide array
incubation mix (50% glycerol, 50 mmol/L adenosine
triphosphate, 0.05% vol/vol Brij-35, 0.25 mg/mL bovine
serum albumin, 33P-g–adenosine triphosphate [1 MBq])
was added to the filtered lysates and the mixture was
loaded onto the microarray chip and allowed to phosphor-
ylate the peptide substrates for 90 minutes at 37C. The
chips were washed twice with TBS 0.1% Triton X-100, twice
in 2 mol/L NaCl, and twice in demineralized water and air-
dried. The slides then were exposed to a phosphor-imager
plate for 72 hours and acquisition of the peptide array
was performed using a phosphor-imager (Storm; Amer-
sham Biosciences, Stockholm, Sweden). Levels of incorpo-
rated radioactivity, which corresponded to the
phosphorylation status, were quantified by the array soft-
ware Scanalyze (Eisen Software) and exported to Microsoft
Excel. As a control, further slides were incubated with 33P-
g–adenosine triphosphate (1 MBq) without cell lysate to
show that the signal observed represented kinase-
dependent covalent transfer of the terminal phosphor atom.
For data analysis, every peptide was first given an “on”
call or “off” call (Markov state analysis). To do this, an
average signal for each peptide first was calculated using
the 3 replicates to yield an aggregate data set for each of the
experimental conditions. Subsequently, for each of the
aggregate data sets, an “on” call or an “off” call was given to
each peptide substrate (Markov state analysis). To do this,
we assumed that the subset of signals representing the 1-e-1
fraction of peptides having the lowest phosphorylation of all
peptides contained pure noise and did not represent
meaningful phosphorylation. The distribution of this noise
was fitted as a single exponent, using the amplitude-sorted
row number of these substrates as the X domain of the
distribution and this single exponent was assumed to
describe noise for the entire data set for this experimental
condition. Now, for all data points within the subset, when
the actual amplitude observed minus 1,96 the standard
deviation was in excess of the value expected from the
distribution describing the noise, a substrate was given an
“on” call. For further analysis, peptides were grouped in
signal transduction categories and the number of “on” calls
in each category was compared for the different experi-
mental conditions and subjected to Galton statistics. Attri-
bution of peptides to signal transduction categories as well
as the number of “on” calls in each category can be found in
Supplementary Figure 3. Results then were grouped into 8
broad biological processes for first analysis by contrasting
activities in these broad groups and then mined for detailed
elucidation of the signaling evoked by BMPR2 in SMAD4-
negative cancer cells.
Orthotopic Metastasis Mouse Model
Development of luciferase expressing cell
line. HT29-cells were stably transfected with a pGL4 vec-
tor expressing firefly luciferase controlled by a CAGGS
promoter. The transfected cells were selected using G418
(500 mg/mL).
Intrasplenic cell injection. Liver metastasis were
generated by injecting 0.5*106 HT29 cells expressing lucif-
erase dissolved in 50 mL of medium:Matrigel (1:1) into the
spleens of 6-week-old immunocompromised CD1 nude mice
(males). Mice were purchased from Charles River Labora-
tories International, Inc (Wilmington, MA).
The mice were anesthetized with isoflurane. A dorsal
subcostal incision was made to expose the spleen. The
spleen was exteriorized and placed on gauze soaked in PBS.
The volume (50 mL) of tumor cell suspension was injected
slowly into the spleen using a 25-gauge needle.
Treatment and analysis. The mice were treated by
intraperitoneal injection with 2.5 mg/kg Y-27632 (R&D
Systems) dissolved in PBS (n ¼ 9) or with PBS (n ¼ 9) every
other day. Weekly scans were performed by intraperitoneal
injection of 100 mL luciferin (25 mg/mL) and tumor for-
mation was visualized using the IVIS Lumina Imaging sys-
tem (Xenogen, Hopkinton, MA). Living Image software
(Caliper, Hopkinton, MA) was used to analyze and quantify
the scans. After 7 weeks the mice were euthanized. The
weight and volume of the livers was determined for each
mouse.
Tissue Microarray
A tissue microarray containing colorectal cancer tissue
from 145 was constructed from formalin-fixed, paraffin-
embedded tissues from the archives of the Pathology
July 2014 Loss of SMAD4 Alters BMP Signaling 208.e3
Department at the Academic Medical Centre and the Pa-
thology Department at the Leiden University Medical Cen-
ter. Three 2-mm cores of tissue from each patient were
included on the array. One core from the corresponding
normal colon and 2 cores from carefully selected repre-
sentative areas of the tumor were included (Supplementary
Table 4).
Immunohistochemistry
SMAD4, BMPR2, and TGFbR2. Sections were depar-
affinized, rehydrated in graded ethanol, and immersed in
0.3% hydrogen peroxide in methanol for 20 minutes to
block endogenous peroxidase activity and antigen retrieval
was performed in 1  Tris/EDTA, pH 9.0, for 30 minutes at
97C. Nonspecific binding sides were blocked with 10%
normal goat serum for 20 minutes. Primary antibody incu-
bation was performed for 1 hour at room temperature
(diluted in PBS/0.1% Triton/1% bovine serum albumin; see
Supplementary Table 5 for concentration). Subsequently,
the LSABþ System–horseradish peroxidase detection sys-
tem (Dako) was used. Peroxidase activity was detected with
fastDAB (Sigma-Aldrich).
BMPR1A, BMPR1B, and TGFbR1. Sections were
deparaffinized, rehydrated in graded ethanol, and immersed
in 0.3% hydrogen peroxide in methanol for 30 minutes.
Antigen retrieval was performed by heating for 10 minutes
to 97C in sodium citrate, pH 6.0, and nonspecific binding
sides were blocked by incubation with 10 mmol/L Tris,
5 mmol/L EDTA, 0.15 mol/L NaCl, 0.25% gelatin, and 0.05%
Tween 20, pH 8.0 for 10 minutes. Antibodies were diluted in
PBS/0.1% Triton/1% bovine serum albumin (see
Supplementary Table 5 for concentration). Incubation took
place overnight at 4C and subsequently the LSABþ
System–horseradish-peroxidase detection system (Dako)
was used. Peroxidase activity was detected with fastDAB
(Sigma-Aldrich).
TMA Analysis
Analysis was performed in a blinded fashion by 2 in-
vestigators independently. SMAD4 expression was scored
according to previously described methods.7 SMAD4 stain-
ing was scored as follows: 0, no staining, 1, weak nuclear
staining or negative nuclear and weak intracytoplasmic
staining in less than 10% of the cells; and 2, moderate to
strong nuclear staining in more than 10% of the cells. The
scoring of TGFb and BMP-receptor staining (BMPR1A,
BMPR1B, BMPR2, TGFbR1, and TGFbR2) was based on both
staining intensity and the percentage of tumor cells stained
as outlined in Supplementary Table 6.
Statistical Analysis
Statistical analysis was performed using the 2-tailed
Student t test, and a P value less than .05 was considered
statistically significant. All experiments were performed
with a minimum of 3 independent experiments. Data are
shown as the mean  SEM. Statistical analysis was per-
formed with Prism 5 for Windows (GraphPad Software, Inc,
La Jolla, CA) using the Student t test and the chi-square test,
and with PASW Statistics 18 for Windows (SPSS, Inc,
Armonk, NY) for the Kaplan–Meier analysis and Cox
regression. The Student t tests were 2-tailed. A P value less
than .05 was considered significant.
References
1. Carlotti F, Bazuine M, Kekarainen T, et al. Lentiviral
vectors efficiently transduce quiescent mature 3T3-L1
adipocytes. Mol Ther 2004;9:209–217.
2. Liv N, Zonnevylle AC, Narvaez AC, et al. Simultaneous
correlative scanning electron and high-NA fluorescence
microscopy. PLoS One 2013;8:e55707.
3. Zonnevylle AC, Van Tol RF, Liv N, et al. Integration of a
high-NA light microscope in a scanning electron micro-
scope. J Microsc 2013;252:58–70.
4. Diks SH, Kok K, O’Toole T, et al. Kinome profiling for
studying lipopolysaccharide signal transduction in hu-
man peripheral blood mononuclear cells. J Biol Chem
2004;279:49206–49213.
5. Tuynman JB, Vermeulen L, Boon EM, et al. Cyclo-
oxygenase-2 inhibition inhibits c-Met kinase activity and
Wnt activity in colon cancer. Cancer Res 2008;68:
1213–1220.
6. van Baal JW, Diks SH, Wanders RJ, et al. Comparison of
kinome profiles of Barrett’s esophagus with normal
squamous esophagus and normal gastric cardia. Cancer
Res 2006;66:11605–11612.
7. Kodach LL, Wiercinska E, de Miranda NF, et al. The bone
morphogenetic protein pathway is inactivated in the
majority of sporadic colorectal cancers. Gastroenter-
ology 2008;134:1332–1341.
208.e4 Voorneveld et al Gastroenterology Vol. 147, No. 1
July 2014 Loss of SMAD4 Alters BMP Signaling 208.e5
=
Supplementary Figure 1. (A and B) HCT116 and HCT116 SMAD4-/- cells were transfected transiently with either BMPR2,
TGF-bR2, or the empty control plasmid pcDNA. After 24 hours, BMP (BRE-luc) and TGF-b (CAGA-luc) activity were measured
using luciferase reporter constructs. (C) HCT116 SMAD4-/- cells were treated with 5 nmol/L and 50 nmol/L of LDN-193189 for
24 hours and compared with a control. Subsequently, mRNA expression levels of E-cadherin and vimentin were measured
using quantitative reverse-transcription polymerase chain reaction. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used a control. (D) HCT116 SMAD4-/- cells were transfected with either pcDNA or a plasmid expressing wild-type
SMAD4. mRNA levels of E-cadherin and vimentin were measured using quantitative reverse-transcription polymerase chain
reaction. (E) Fluorescent immunocytochemistry for E-cadherin and vimentin in SW480 cells. Cells were transfected with either
pcDNA or BMPR2. (F) mRNA expression levels of E-cadherin and vimentin measured using quantitative reverse-transcription
polymerase chain reaction in SW480 and HT-29 (SMAD4-negative) cells transfected with either pcDNA or BMPR2. GAPDH
was used as a control. (G) SW480 (SMAD4-negative) cells were transfected with either pcDNA or BMPR2. mRNA expression
levels of the EMT-associated transcription factors SLUG and ZEB1 were measured using quantitative reverse-transcription
polymerase chain reaction. GAPDH was used as a control. (H) Invasion of LS174T and LS174t shSMAD4 cells measured
over a 36-hour time period in a Matrigel–Transwell system. Cells were labeled with a fluorescence label Cell tracker, and
seeded in the upper chamber of a Transwell system and subsequently treated with 100 ng/mL BMP2 or PBS (control).
(I) Western blot analysis of the small interfering RNA (siRNA) knockdown of BMPR1A, BMPR1B, and BMPR2 in SW480 cells.
Actin was used as a loading control. Cells transfected with nontargeting scrambled siRNA were used as a control. Student t
tests were performed as appropriate (*<0.05, **<0.01, ***< 0.001). Data are presented as means  SEM.
Supplementary Figure 2. HCT116 SMAD4-/- cells were
transfected transiently with either BMPR2 or control pcDNA.
The roundness was calculated as described in the Supple-
mentary Materials and Methods section. HCT116 cells were
used as a SMAD4-positive control. Student t tests were
performed as appropriate (*<0.05, **<0.01, ***< 0.001). Data
are presented as means  SEM.
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Supplementary Figure 4. (A) SW480 cells were treated with different concentrations of the ROCK inhibitor Y-27632 to
evaluate the optimal treatment concentration. Cells were lysed and samples were analyzed by immunoblotting using anti-
bodies against p-cofilin. Actin was used as a loading control. At 2.5 mmol/L the ROCK inhibitor leads to near-maximal inhibition
of p-cofilin. (B) SW480 cells were transfected with either BMPR2 or pcDNA. Subsequently, the cells were treated with 2.5
mmol/L of the ROCK inhibitor Y-27632 in PBS or PBS alone. Cells were lysed and samples were analyzed by immunoblotting.
Blots were exposed to antibodies against p-LIMK1/2 and p-cofilin. Actin was used as a loading control. (C) SW480 cells were
treated with noggin (500 ng/mL), LDN-193189 (5 nmol/L), or BMP-2 ligands (100 ng/mL) for 24 hours. Afterward, cells were
lysed and immunoblotting for protein expression of p-cofilin was performed. Actin was used as a loading control. (D) SW480
cells were transfected with either pcDNA or BMPR2. Afterward, a wound-healing assay was performed to measure cell
migration. The image shows a quantification of the wound closure after 24 hours. (E) Invasion assay of SW480 cells treated
with either PBS (control), BMP-2 (100 ng/mL), ROCK inhibitor (2.5 mmol/L), or a combination of BMP-2 (100 ng/mL) plus a
ROCK inhibitor (2.5 mmol/L). Student t tests were performed as appropriate (*<.05, **<.01, ***<.001). Data are presented as
means  SEM.
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Supplementary Figure 5. (A) HT-29 cells were labeled with Celltracker and seeded in the upper chamber of a Transwell
system. Cells that had migrated through Matrigel into the lower chamber were measured every 2 hours for 48 hours in total.
During the invasion assay cells were treated with PBS or 100 ng/mL BMP-2. (B) HT-29 cells were labeled with Celltracker and
seeded in the upper chamber of a Transwell system. Cells that had migrated through Matrigel into the lower chamber were
measured every 2 hours for 48 hours in total. During the invasion assay cells were treated with PBS or 2.5 mmol/L of the ROCK
inhibitor Y-27632 in PBS. (C) HT-29 cells were treated with 2.5 mmol/L of the ROCK inhibitor Y-27632 in PBS or PBS alone for
48 hours. Cell viability/proliferation was measured using a MTT assay. (D) Correlation between the whole-mouse scans and the
ex vivo liver scans. The association between the quantification of the 2 scans is a log regression, as follows: y ¼
10
ˇ
(1.51*log(x)-2.86). (E) Measurement of the weight of the livers. (F) Measurement of the liver volume. (G) H&E histology liver
sections. Two examples without metastases from the PBS-treated group and 2 examples with metastases from the ROCK
inhibitor group are shown. Student t tests were performed (*<.05, **<.01, ***<.001). Data are presented as means  SEM.
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Supplementary Figure 6. (A) Colorectal cancer tissue of 145 patients was stained for SMAD4, BMPR1A, BMPR1B, and
BMPR2 using immunohistochemistry. The table shows the distribution of the BMP signaling groups. The cancers were first
divided in SMAD4 positive and SMAD4 negative. Then the groups were subdivided into BMPR-positive or BMPR-negative
subgroups. (C) Analysis similar to panel B only using TGFb-receptor expression instead of BMP-receptor expression.
(D) Distribution of the tumor stages within the groups based on SMAD4 and BMP-receptor expression.
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Supplementary Table 1.Kinase Inhibitors
Substance Function/inhibits Concentration used IC50 Company
hBMP-2 BMP ligand (activates BMP) 100 ng/mL - R&D systems
hNoggin BMP 500 ng/mL - R&D systems
LDN-193189 BMPR1A 5 nmol/L 5 nmol/L AxonMedchem
Y-27632 ROCK 2.5 mmol/L 2–10 mmol/L Cayman/Millipore
PD-098059 MEK/ERK 10 mmol/L 10 mmol/L Cayman/Sigma
SP-600125 JNK 20 mmol/L 5–20 mmol/L Cayman/Sigma
LY-294002 Phosphoinositide 3-kinase 10 mmol/L 10 mmol/L Cayman/Sigma
H-7 Protein kinase A and Protein kinase C 10 mmol/L 10 mmol/L Cayman
SC-514 IkB kinase 2 (IKK2) 12 mmol/L 3–12 mmol/L Cayman
Tyrphostin AG 1295 platelet-derived growth factor 0.5 mmol/L 0.5 mmol/L Cayman
Damnacanthal p56 lymphocyte-specific protein tyrosine
kinase
620 nmol/L 620 nmol/L Cayman
Piceatannol Spleen tyrosine kinase 10 mmol/L 10 mmol/L Cayman
AG-490 Janus kinase 2 10 mmol/L 10 mmol/L Cayman
KN-93 Calmodulin-dependent protein kinase II 370 nmol/L 370 nmol/L Cayman
ML-7 Myosin light chain kinase 0.5 mmol/L 0.5 mmol/L Cayman
N9-isopropyl-olomourcine Cyclin-dependent kinase 1/cyclin B en
CDK5/p35
3 mmol/L 2 and 3 mmol/L Cayman
Roscovitine CDK2/cyclin E 0.1 mmol/L 0.1 mmol/L Cayman
ZM 336372 murine leukemia viral oncogene
homolog 1
70 nmol/L 70 nmol/L Cayman
LFM-A13 Bruton’s tyrosine kinase and Polo-like
kinase
10 mmol/L 2.5 and 10 mmol/L Cayman
Indirubin Cyclin-dependent kinases and GSK-3b
inhibitor
75 nmol/L 75 nmol/L and 0.19 mmol/L Cayman
Apigenin Casein Kinase activity 30 mmol/L 30 mmol/L Cayman
Rapamycin mammalian target of rapamyci 0.1 nmol/L 0.1 nmol/L Cayman
BML-257 AKT1 100 nmol/L 64 and 98 nmol/L Cayman
NOTE. For the treatment of cancer cell line cells, the median inhibitory concentration for each specific kinase was used.
IC50, median inhibitory concentration.
Supplementary Table 2.Primer Sequences
Gene Forward (‘5-‘3) Reverse (‘5-‘3)






NOTE. Primers were manufactured by Invitrogen (except for CDH-1, which was purchased from Qiagen).
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Supplementary Table 3.List of Primary Antibodies for Immunoblotting
Protein Phospho site Clone Company Product number Source Size, kD Dilution
E-cadherin - G-10 Santa Cruz sc-8226 Mouse monoclonal 120 1:200
Vimentin - R28 Cell Signaling 3932 Rabbit polyclonal 57.5 1:500
ACTIN - I-19 Santa Cruz sc-1616 Rabbit polyclonal 43 1:10,000
p-AKT Thr308 - Cell Signaling 9275 Rabbit polyclonal 60 1:500
p-p38 MAPK Thr180/Tyr182 3D7 Cell Signaling 9215 Rabbit polyclonal 43 1:500
p-MKK3/6 Ser189/Ser207 - Cell Signaling 9231 Rabbit polyclonal 40/41 1:500
p-JNK Thr183/Tyr185 - Cell Signaling 9251 Rabbit polyclonal 46/54 1:500
p-ERK1/2 Thr202/Tyr204 20G11 Cell Signaling 4376 Rabbit monoclonal 42/44 1:500
p-GSKa/b Ser21/9 - Cell Signaling 9331 Rabbit polyclonal 46/51 1:500
SIP1 - - Sigma-Aldrich SAB1406675 Mouse polyclonal 31.6 1:500
p-Cofilin Ser3 77G2 Cell Signaling 3313 Rabbit monoclonal 19 1:500
p-LIMK1/2 Thr508/Thr505 - Cell Signaling 3841 Rabbit polyclonal 72 1:500
BMPR1A - H-60 Santa Cruz sc-20736 Rabbit polyclonal 66 1:200
BMPR1B - H-44 Santa Cruz sc-25455 Rabbit polyclonal 50 1:200
BMPR2 - G-25 Santa Cruz sc-130704 Rabbit polyclonal 115 1:200
SMAD4 - B-8 Santa Cruz sc-7966 Mouse monoclonal 61 1:500
NOTE. All secondary horseradish-peroxidase–conjugated antibodies were obtained from Dako (Glostrup, Denmark).
Supplementary Table 4.Patient Characteristics
Total, n ¼ 145 (%)










Poorly differentiated 15/102 (14.7)
Moderately differentiated 66/102 (64.7)
Well differentiated 21/102 (20.6)
Locationb
Left sidedc 80/97 (82.5)
Right sidedd 17/97 (17.5)
aKnown for 102 of the 145 patients.
bKnown for 97 of the 145 patients.
cLeft sided is defined as rectosigmoid, sigmoid, and
descending colon.
dRight sided is defined as splenic flexure, transverse colon,
hepatic flexure, ascending colon, and cecum.
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Supplementary Table 5.List of Primary Antibodies for Immunohistochemistry
Protein Company Category number Source Antigen retrieval Blocking Incubation Dilution
BMPR1A R&D Systems MAB24061 Mouse monoclonal Tris/EDTA Goat serum 1 hour at RT 1:100
BMPR1B R&D Systems MAB5051 Mouse monoclonal Tris/EDTA Goat serum 1 hour at RT 1:100
BMPR2 R&D Systems AF811 Goat polyclonal Citrate TENG-T Overnight at 4C 1:100
TGFbR1 Santa Cruz H-100 Rabbit polyclonal Tris/EDTA Goat serum 1 hour at RT 1:100
TGFbR2 Santa Cruz L-21 Rabbit polyclonal Citrate TENG-T Overnight at 4C 1:100
SMAD4 Santa Cruz B-8 Mouse monoclonal Citrate TENG-T Overnight at 4C 1:100
RT, room temperature; TENG-T, 10 mmol/L Tris, 5 mmol/L EDTA, 0.15 mol/L NaCl, 0.25% gelatin, and 0.05% Tween 20,
pH 8.0.
Supplementary Table 6.Scoring System for BMP/TGFb-
Receptor Immunohistochemistry
Intensity of staining
Percentage of cells stained
<10% 10%–30% >30%
No 0 0 0
Weak 0 0 1
Moderate 0 1 2
Strong 0 2 4
NOTE. A BMP/TGFb-receptor expression score of 0 or 1 is
considered negative. A score of 2 or 3 is considered positive.
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